The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar ...

Metformin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. Weight loss is recognized as a side effect of metformin, and many people who treat their ...

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner, Innovent, has bested Novo Nordisk’s reigning GLP-1 semaglutide, in a phase 3 study across both blood ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Three new studies shed light on some common questions about atrial fibrillation: whether your morning coffee matters, whether ...

We speak to pharmacist Oonagh O’Hagan on everything you need to know about diabetes, from the signs and symptoms, to the ...

GLORY-2 (NCT06164873) is a Phase 3 clinical study to evaluate the efficacy and safety of mazdutide 9 mg combined with lifestyle intervention versus placebo in Chinese adults with obesity (BMI ≥30 ...

Ingredient Supplementation Creates New Category as Industry Addresses Widespread Consumer Confusion About FDA Regulation, ...